TRPV1 modulated NLRP3 inflammasome activation via calcium in experimental subarachnoid hemorrhage

doi:10.21203/rs.3.rs-1750537/v1

Download PDF

Research Article

TRPV1 modulated NLRP3 inflammasome activation via calcium in experimental subarachnoid hemorrhage

https://doi.org/10.21203/rs.3.rs-1750537/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Neuroinflammation plays a key role in early brain injury (EBI) of subarachnoid hemorrhage (SAH), and NLRP3 inflammasome plays an important role in the development of neuroinflammation after SAH, but the mechanism of NLRP3 inflammasome activation after SAH is still unclear. TRPV1 is a non-selective calcium channel that is involved in the pathology of neuroinflammation, but its role in SAH has not been revealed. Our study showed that TRPV1 was significantly upregulated after SAH and was predominantly expressed in microglia/macrophages. Antagonism of TRPV1 was effective in ameliorating neurological impairment, brain edema, neuronal damage, and reducing the inflammatory response (evidenced by reducing the number of CD16/32 positive microglia/macrophages, inhibiting the expression of CD16, CD32, CD86, IL-1b, TNF-a and blocking NLRP3 inflammasome activation). However, this effect can be abolished by NLRP3 inflammasome antagonist MCC950. In vitro experiment confirmed that TRPV1 activated NLRP3 inflammasome by increasing intracellular calcium levels. In conclusion, TRPV1 mediates EBI after SAH via calcium/NLRP3, and TRPV1 is a potential therapeutic target after SAH.

subarachnoid hemorrhage

early brain injury

neuroinflammation

TRPV1

NLRP3 inflammasome

Subarachnoid hemorrhage (SAH) is an acute cerebrovascular disease with high mortality and morbidity, mainly caused by the rupture of intracranial aneurysms[1]. Early brain injury (EBI) is one of the main factors for the poor prognosis of SAH patients. A large number of evidence indicate that neuroinflammation is the main pathophysiological mechanism of EBI. Inhibiting the inflammatory response after SAH can effectively alleviate EBI and significantly promote the recovery of neurological function after SAH[2]. The NLRP3 inflammasome is a multi-protein complex associated with various inflammatory diseases[3]. The NLRP3 protein consists of an amino-terminal pyrin domain (PYD), a NACHT domain, and a carboxy-terminal leucine-rich (LRR) repeat domain[4]. The PYD domain of NLRP3 binds to the PYD domain of ASC and then recruits inactive caspases-1 through the interaction of ASC with the common recruitment domain (CARD) to form the NLRP3 inflammasome. Activation of the NLRP3 inflammasome cleaves pro-caspase-1 into active caspase-1, which induces the pro-inflammatory cytokine IL-1β and IL-18 process and secretion, and causes inflammatory response[5].

Recent studies have been gradually revealing the effects of NLRP3 on the occurrence and development of the central nervous system. In the pathological process of Alzheimer's disease, abnormally activated NLRP3 inflammasome can lead to pathological damage of neurons and accelerate the deterioration of neural function[6]. Soares et al. have reported that in a mouse model of multiple sclerosis, pharmacological inhibition of NLRP3 activation can significantly reduce neuroinflammation and promote the improvement of motor function[7]. In addition to the above-mentioned chronic neurodegenerative diseases, studies have confirmed that NLRP3 inflammasome activated after SAH, and inhibition of NLRP3 inflammasome can alleviate EBI after SAH[8, 9]. However, the mechanism of the NLRP3 inflammasome activation is very complex, including abnormal distribution of intracellular ions (potassium, calcium, and chloride ions)[10–16], oxidized mitochondrial DNA (ox-mtDNA)[17], unstable soluble Enzymes[18] and reactive oxygen species (ROS)[19, 20]. The disruption of intracellular ion homeostasis has been considered to be one of the most important factors in inducing NLRP3 inflammasome activation. Recent studies have shown that calcium ions influx or migration plays an important role in the activation of the NLRP3 inflammasome[21–23], however, whether calcium ions are involved in NLRP3 inflammasome activation after SAH and the underlying mechanisms involved remains unclear.

TRPV1, also known as vanilloid receptor type 1(VR1), is a member of the transient receptor potential channel protein family. Previous studies have focused on the role of TRPV1 in sensory transmission from nociceptive neurons in the peripheral nervous system[24]. Recent reports indicated that TRPV1 was widely distributed in the central nervous system, and it may involve regulating the neuroinflammatory processes[25]. Moreover, some studies have pointed out that TRPV1 regulated neuroinflammation by activating the NLRP3 inflammasome[26–28]. Herein, we speculate that TRPV1 and associated NLRP3 inflammasome might play an essential role in SAH-induced neuroinflammation.

Mouse models of SAH and drugs administration

C57BL/6 mice (male, 22-25g) were purchased from Vital River Laboratory Animal Technology (Beijing, China). The procedures involved in mice were conformed to the guidelines of the National Institutes of Health on the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee of Shandong First Medical University.

SAH model was constructed via endovascular perforation as the previous study[29]. Briefly, After the mice were anesthetized, the nylon suture was passed through the external carotid artery to the bifurcation of the anterior and middle artery and ultimately punctured to cause blood to flow into the subarachnoid space.

Mice were injected with 30 mg/kg capsazepine (CPZ) subcutaneously or 10mg/kg capsaicin (CAP) intraperitoneally post-modeling to inhibit or active TRPV1[27, 30], respectively. MCC950 (40 mg/kg) were intraperitoneally injected post-modeling and 12h later[9]. The drugs above were all purchased from MedChemExpress.

Magnetic-activated cell sorting (MACS) and qPCR analysis

Ipsilateral hemispheres were harvested at 24h post-SAH, dissociated mechanically using a glass homogenizer, and filtered into a 70-μm strainer to obtain a single-cell suspension. The single-cell suspension was isolated with 30% Percoll solutions, incubated with CD11b microbeads (Miltenyi Biotec, Germany, 130-126-725), and then divided into CD11b positive and negative cells.

Total mRNA of tissues and cells was extracted using TRIzol™ Reagent (Life Technologies, USA), used to synthesize cDNA using Evo M-MLV Reverse Transcriptase (Takara, Japan, RR420A), and then performed the qPCR analysis using SYBR Premix Ex Taq™ Kit (Takara, Japan, RR036A) according to manufacturer’s protocol. The primers were listed in Supplementary Table 1.

Brain water content

The ipsilateral hemisphere was harvested 24h after SAH and weighed to obtain the wet weight, followed immediately by drying at 105℃ for 3 days and then obtaining the dry weight. The brain water content was calculated as the wet weight minus the dry weight and then divided by the wet weight.

Neurobehavioral assessment

Neurobehavioral assessment containing modified Garcia and beam balance test was performed 24h post-SAH to evaluate neurological function[31]. Modified Garcia and beam balance scores ranged from 3 to 18 and 0 to 4 respectively, with higher scores indicating better neurological function.

Histological staining analysis

Mice were anesthetized and perfused sufficiently with 4% paraformaldehyde (PFA) at 24h after SAH to harvest the brain tissues. The brain tissues were fixed in 4% PFA for 24h, dehydrated in 30% sucrose solution, embedded in OCT compound, and then sliced into 10μm coronal sections for immunofluorescence and Nissl staining analysis.

For immunofluorescence staining analysis, mice brain sections were blocked and permeabilized with 5% bovine serum containing 0.3% Triton-X100 for 1h at room temperature and incubated with primary antibodies overnight at 4°C followed by 1 hour incubation at room temperature with the corresponding secondary antibody. The primary antibodies included anti-Iba-1 (Abcam, Cambridge, UK, ab-5076), anti-TRPV1(Abcam, Cambridge, UK, ab203103), and anti-CD16/CD32 antibody (Biolegend, USA, 101329).

For Nissl staining, mice brain sections were stained with 0.5% cresyl violet for 0.5h at room temperature and dehydrated with ethanol absolute[32]. The images were analyzed using Image J (NIH).

Western blot

Proteins of tissues and cells were extracted using RIPA lysis buffer(Beyotime, Shanghai, China, P0013B), separated by SDS-PAGE, transferred into PVDF membrane, blocked with 5% non-fat powdered milk, incubated with primary antibodies overnight at 4°C followed by 1 hour incubation at room temperature with the corresponding secondary antibody. Then, the PVDF membrane was visualized using the ECL Plus chemiluminescence reagent kit. The primary antibodies included anti-β-actin (Proteintech, Hubei, China, 60008-1-Ig), anti-ZO-1 (Santa Cruz, TX, USA, sc-33725), anti-claudin-5 (Santa Cruz, TX, USA, sc-28670), anti-occludin (Santa Cruz, TX, USA, sc-133256), anti-NLRP3(Abcam, Cambridge, UK, ab210491), anti-ASC (Santa Cruz, TX, USA, sc-271054), anti-caspase-1 p20 (Santa Cruz, TX, USA,sc-22165). The protein expression was quantified using Image J (NIH).

ELISA

The total protein content of tissues and cell culture supernatants was determined via BCA assay (Beyotime, China). The expression level of IL-1β was detected using ELISA kit (Boster, Wuhan, China, EK0394) according to the manufacturer’s protocol.

In vitro SAH model

Murine BV2 cells were stimulated by 200μM hemin (Sigma-Aldrich, MO, USA, H9039) to establish the SAH model in vitro. Meanwhile, BV2 cells were treated with 10μM CAP[33] and BAPTA-AM[27] to investigate the mechanism of the TRPV1-activated NLRP3 inflammasome.

Calcium concentration detection

Calcium concentration was detected as previously reported[34]. Briefly, BV2 cells were incubated with 4μM Fura-2/AM (YEASEN, Shanghai, China, 40702ES50) for 30min, and captured the fluorescence intensities when excited at 340 and 380 nm and emitted at 510nm. The calcium concentration was calculated as followed: the fluorescence intensities at 340nm/ the fluorescence intensities at 380nm.

Statistical Analysis

The data were analyzed by SPSS 22.0 and GraphPad Prism 8.0 to test whether met the normal distribution and variance homogeneity by Shapiro-Wilk and Levene methods, respectively. When met, data were analyzed by Student’s t-test (two groups) or one-way analysis of variance (ANOVA) with Tukey’s post hoc contrasts (more than three groups); otherwise, data were analyzed by Mann–Whitney nonparametric test (two groups) and Kruskal-Wallis test with post hoc contrast by the Dunn-Bonferroni test (more than three groups).

TRPV1 upregulated post-SAH

qPCR results showed that the mRNA level of Trpv1 was increased at 24 h post-SAH (Fig. 1A). Using MACS to divide the brain cells into CD11b positive and negative cells, it was found that Trpv1 changed most significantly in CD11b positive cells (Fig. 1B). Consistently, immunofluorescence staining demonstrated that TRPV1 was mainly expressed in microglia/macrophages (Fig. 1C).

Antagonism of TRPV1 attenuated neurological dysfunction

CPZ, a selective TRPV1 antagonist, was introduced to investigate the effect of TRPV1 on neurological impairment. Neurobehavioral scores including modified Garcia scores and beam scores showed severe neurological dysfunction after SAH when compared with the sham group. However, blockage of TRPV1 with CPZ improved the neurological dysfunction (Figure 2A, B). The administration of CPZ dramatically reduced the brain water content and upregulated the expression of tight junction proteins including ZO-1, occluding, and claudin-5 (Figure 2C-G). Nissl staining also showed that CPZ increased the number of neurons (Figure 2H, I).

Antagonism of TRPV1 alleviated the neuroinflammation

Immunofluorescence staining demonstrated that the number of CD16/32 positive microglia/macrophages increased after SAH and reduced after treatment with CPZ (Figure 3A). Consistent with immunofluorescence staining, the mRNA level of CD16, CD32, CD86, IL-1β, and TNF-α elevated in the SAH+vehicle group whereas declined in the SAH+CPZ group (Figure 3B-F). Subsequently, we detected whether TRPV1 was involved in the activation of the NLRP3 inflammasome. The western blot results showed that the expression of NLRP3, ASC, and caspase-1 p20 were increased in the SAH+vehicle group and reduced in the SAH+CPZ group (Figure 4A-D). The level of IL-1β showed a similar change determined via ELISA (Figure 4E).

TRPV1 enhanced neuroinflammation via the NLRP3 inflammasome

To investigate the effect of NLRP3 inflammasome on TRPV1 induced neuroinflammation, CAP, a selective TRPV1 agonist, and MCC950, a selective TRPV1 antagonist, were introduced to active TRPV1 and inhibit NLRP3, respectively. Administration of CAP decreased the modified Garcia and beam scores and increased the brain water content compared with the SAH+vehicle group, while inhibition NLRP3 with MCC950 reversed the aggravation of neurobehavioral assessment and brain water content (Figure 5A-C). Data from ELISA and qPCR confirmed that MCC950 inhibited the elevation of the level of IL-1β, TNF-α, CD16, CD32, and CD86 induced by CAP (Figure 5D-I).

TRPV1 activated NLRP3 inflammasome via calcium

Given the essential role of TRPV1 in regulating calcium homeostasis and the involvement of calcium in NLRP3 inflammasome activation, calcium was introduced to investigate the underlying mechanism by which TRPV1 induced NLRP3 inflammasome activation. Calcium content of microglia was dramatically increased when stimulated with hemin while reduced when the administration of CPZ (Figure 6A). Chelation of calcium via BAPTA-AM reversed the increased level of NLRP3, ASC, caspase-1 p20, and IL-1β induced by hemin (Figure 6B-F).

As TRPV1 is not only expressed in peripheral sensory neurons but also widely expressed in the central nervous system, attention has gradually moved beyond its classical role as a pain sensor to focus on its role in the central nervous system[35–37]. Although many studies have pointed to the indispensability of TRPV1 in the central nervous system, particularly in the pathology of the inflammatory response, it is a puzzle to conclude exactly what role it plays, as it exhibits deteriorated or protective effects in the context of diseases[38, 39]. For deteriorated effects, the selective TRPV1 antagonists CPZ inhibited the morphine-induced increased expression of p38 MAPK and NF-κB[40]. Additionally, Miyanohara et al confirmed that both TRPV1 knockout and CPZ showed an alleviated neurological function after stroke[41]. For the protective effects, TRPV1 suppressed the oxidative stress and enhanced the endogenous production of a neurotrophic factor in the neurodegeneration diseases including Parkinson’s disease[42], vascular dementia[43], and Huntington’s disease[44]. The mechanism was at least in part related to the anti-inflammatory effect[45–47]. Hence, it is essential to determine the specific effect of TRPV1 in the context of SAH. We found that CPZ inhibited TRPV1 alleviated the neurological function injury, BBB disruption and reduced the pro-inflammatory microglia, and was associated with the inflammatory response, indicating the deteriorated effects of TRPV1 after SAH.

Since TRPV1 was mainly expressed in microglia/macrophages and microglia/macrophages were thought to be one of the most important factors mediating the inflammatory response after SAH, we hypothesize that the brain injury effect of TRPV1 after SAH might be mainly due to its pro-inflammatory effect. The pro-inflammatory mechanism of TRPV1 remains unclear, however, there were some recent studies linking it to NLRP3 inflammasome[26–28, 48]. Moreover, growing evidence suggested that the NLRP3 inflammasome was involved in the inflammatory response after SAH, that inhibition of the NLRP3 inflammasome significantly alleviates neurological dysfunction, and that the NLRP3 inflammasome activation mechanisms after SAH related to SIRT1, NRF2, AMPK, etc[9, 49–51]. However, the effect of TRPV1 on the NLRP3 inflammasome activation has not been determined in SAH. Our data confirmed that the expression of NLRP3 inflammasome-related proteins NLRP3, ASC, and caspase-1 p20 were down-regulated after pharmacological antagonism of TRPV1, and the level of inflammatory cytokine IL-1β was significantly decreased. Furthermore, inhibiting the NLRP3 inflammasome abolished the TRPV1 mediating the neurological dysfunction and inflammatory response. Since calcium ions can mediate NLRP3 inflammasome activation and TRPV1 can act as a non-selective calcium channel, we next explored the role of calcium ions on TRPV1-mediated NLRP3 inflammasome activation in vitro. The data showed that suppressing the TRPV1 reduced the calcium ion contents in BV2 cells. Moreover, chelated calcium ions reversed the TRPV1 mediating NLRP3 inflammasome activation. Previous studies have found that two mechanisms might be involved in calcium-mediated NLRP3 inflammasome activation: (1) promoting the interaction between NLRP3 and ASC to mediate the activation of NLRP3 inflammasome; (2) causing mitochondrial calcium overload that leads to mitochondrial damage, which in turn released ROS, ox-mtDNA to activate the NLRP3 inflammasome[52], but the mechanism under TRPV1-mediated calcium influx and NLRP3 activation remain to be defined. Zhang et al revealed that calcium ion influx via TRPV1 directly bound to PP2A thus to active NLRP3 inflammasome in EAE[27], however, the specific mechanism in SAH needs further study.

In conclusion, our data showed that TRPV1 modulated NLRP3 inflammasome activation via calcium and that antagonizing TRPV1 significantly improves EBI after SAH (Fig. 7). Targeting TRPV1 might be a promising therapeutic strategy for SAH.

Author contributions ZZ and ZKK conceived and designed the research. ZKK and GGY constructed the SAH model, PCR, and immunofluorescence stain. GGY and WHC performed the experiment in vitro. CJY and WF performed the western blot and Nissl staining. ZKK and ZZ wrote and edited the manuscript. All authors read, corrected, and approved the final manuscript.

Funding This work was supported by the Natural Science Foundation of Shandong Province (No. ZR2021MH228)

Data Availability All raw data used in this manuscript are available on reasonable request.

Ethics Approval The procedures involved in mice were conformed to the guidelines of the National Institutes of Health on the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee of Shandong First Medical University.

Consent for Publication Not applicable.

Competing Interests The authors declare no conflict of interest.

Ji, C. and G. Chen, Signaling Pathway in Early Brain Injury after Subarachnoid Hemorrhage: News Update. Acta Neurochir Suppl, 2016. 121: p. 123–6 DOI: 10.1007/978-3-319-18497-5_21.
Xie, Z., et al., Recombinant Netrin-1 binding UNC5B receptor attenuates neuroinflammation and brain injury via PPARgamma/NFkappaB signaling pathway after subarachnoid hemorrhage in rats. Brain Behav Immun, 2018. 69: p. 190–202 DOI: 10.1016/j.bbi.2017.11.012.
Abderrazak, A., et al., NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol, 2015. 4: p. 296–307 DOI: 10.1016/j.redox.2015.01.008.
Mariathasan, S. and D.M. Monack, Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol, 2007. 7(1): p. 31–40 DOI: 10.1038/nri1997.
Heneka, M.T., R.M. McManus, and E. Latz, Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci, 2018. 19(10): p. 610–621 DOI: 10.1038/s41583-018-0055-7.
Ren, Q.G., et al., Spatial Training Ameliorates Long-Term Alzheimer's Disease-Like Pathological Deficits by Reducing NLRP3 Inflammasomes in PR5 Mice. Neurotherapeutics, 2019. 16(2): p. 450–464 DOI: 10.1007/s13311-018-00698-w.
Soares, J.L., E.M. Oliveira, and A. Pontillo, Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis. Mult Scler Relat Disord, 2019. 29: p. 26–34 DOI: 10.1016/j.msard.2019.01.023.
Zhou, K., et al., RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol, 2017. 295: p. 116–124 DOI: 10.1016/j.expneurol.2017.06.003.
Dodd, W.S., et al., NLRP3 inhibition attenuates early brain injury and delayed cerebral vasospasm after subarachnoid hemorrhage. J Neuroinflammation, 2021. 18(1): p. 163 DOI: 10.1186/s12974-021-02207-x.
Munoz-Planillo, R., et al., K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity, 2013. 38(6): p. 1142–53 DOI: 10.1016/j.immuni.2013.05.016.
Green, J.P., et al., Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc Natl Acad Sci U S A, 2018. 115(40): p. E9371-E9380 DOI: 10.1073/pnas.1812744115.
Lee, G.S., et al., The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2 + and cAMP. Nature, 2012. 492(7427): p. 123–7 DOI: 10.1038/nature11588.
Murakami, T., et al., Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A, 2012. 109(28): p. 11282–7 DOI: 10.1073/pnas.1117765109.
Petrilli, V., et al., Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ, 2007. 14(9): p. 1583–9 DOI: 10.1038/sj.cdd.4402195.
Tang, T., et al., CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun, 2017. 8(1): p. 202 DOI: 10.1038/s41467-017-00227-x.
Vaeth, M., et al., Ca2 + Signaling but Not Store-Operated Ca2 + Entry Is Required for the Function of Macrophages and Dendritic Cells. J Immunol, 2015. 195(3): p. 1202–17 DOI: 10.4049/jimmunol.1403013.
Park, S., et al., The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol, 2013. 191(8): p. 4358–66 DOI: 10.4049/jimmunol.1301170.
Okada, M., et al., The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem, 2014. 289(47): p. 32926–36 DOI: 10.1074/jbc.M114.579961.
Aminzadeh, M., et al., TRPM2 dependence of ROS-induced NLRP3 activation in Alzheimer's disease. Int Immunopharmacol, 2018. 54: p. 78–85 DOI: 10.1016/j.intimp.2017.10.024.
Zhong, Z., et al., TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun, 2013. 4: p. 1611 DOI: 10.1038/ncomms2608.
Tseng, H.H., et al., TRPM2 regulates TXNIP-mediated NLRP3 inflammasome activation via interaction with p47 phox under high glucose in human monocytic cells. Sci Rep, 2016. 6: p. 35016 DOI: 10.1038/srep35016.
Compan, V., et al., Cell volume regulation modulates NLRP3 inflammasome activation. Immunity, 2012. 37(3): p. 487–500 DOI: 10.1016/j.immuni.2012.06.013.
Wang, M., et al., Roles of TRPA1 and TRPV1 in cigarette smoke -induced airway epithelial cell injury model. Free Radic Biol Med, 2019. 134: p. 229–238 DOI: 10.1016/j.freeradbiomed.2019.01.004.
Ho, K.W., N.J. Ward, and D.J. Calkins, TRPV1: a stress response protein in the central nervous system. Am J Neurodegener Dis, 2012. 1(1): p. 1–14.
Martins, D., I. Tavares, and C. Morgado, "Hotheaded": the role OF TRPV1 in brain functions. Neuropharmacology, 2014. 85: p. 151-7 DOI: 10.1016/j.neuropharm.2014.05.034.
Lin, Y., et al., TRPV1 Suppressed NLRP3 Through Regulating Autophagy in Microglia After Ischemia-Reperfusion Injury. J Mol Neurosci, 2022. 72(4): p. 792–801 DOI: 10.1007/s12031-021-01935-2.
Zhang, Y., et al., TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia. Cell Death Dis, 2021. 12(12): p. 1159 DOI: 10.1038/s41419-021-04450-9.
Luo, J., et al., 6-Gingerol protects against cerebral ischemia/reperfusion injury by inhibiting NLRP3 inflammasome and apoptosis via TRPV1 / FAF1 complex dissociation-mediated autophagy. Int Immunopharmacol, 2021. 100: p. 108146 DOI: 10.1016/j.intimp.2021.108146.
Zeng, H., et al., Autophagy protein NRBF2 attenuates endoplasmic reticulum stress-associated neuroinflammation and oxidative stress via promoting autophagosome maturation by interacting with Rab7 after SAH. J Neuroinflammation, 2021. 18(1): p. 210 DOI: 10.1186/s12974-021-02270-4.
Anandakumar, P., et al., Capsaicin provokes apoptosis and restricts benzo(a)pyrene induced lung tumorigenesis in Swiss albino mice. Int Immunopharmacol, 2013. 17(2): p. 254–9 DOI: 10.1016/j.intimp.2013.05.015.
Wu, X., et al., TREM1 Regulates Neuroinflammatory Injury by Modulate Proinflammatory Subtype Transition of Microglia and Formation of Neutrophil Extracellular Traps via Interaction With SYK in Experimental Subarachnoid Hemorrhage. Front Immunol, 2021. 12: p. 766178 DOI: 10.3389/fimmu.2021.766178.
Chen, H., et al., Activation of Nurr1 with Amodiaquine Protected Neuron and Alleviated Neuroinflammation after Subarachnoid Hemorrhage in Rats. Oxidative Medicine and Cellular Longevity, 2021. 2021 DOI: 10.1155/2021/6669787.
Wang, C., et al., TRPV1-Mediated Microglial Autophagy Attenuates Alzheimer's Disease-Associated Pathology and Cognitive Decline. Front Pharmacol, 2021. 12: p. 763866 DOI: 10.3389/fphar.2021.763866.
Sha'fie, M.S.A., et al., Ethanol Induces Microglial Cell Death via the NOX/ROS/PARP/TRPM2 Signalling Pathway. Antioxidants (Basel), 2020. 9(12) DOI: 10.3390/antiox9121253.
Tsuji, F., et al., Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents. Eur J Pharmacol, 2010. 627(1–3): p. 332–9 DOI: 10.1016/j.ejphar.2009.10.044.
Balleza-Tapia, H., et al., TrpV1 receptor activation rescues neuronal function and network gamma oscillations from Abeta-induced impairment in mouse hippocampus in vitro. Elife, 2018. 7 DOI: 10.7554/eLife.37703.
Marrone, M.C., et al., TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun, 2017. 8: p. 15292 DOI: 10.1038/ncomms15292.
Alawi, K. and J. Keeble, The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther, 2010. 125(2): p. 181–95 DOI: 10.1016/j.pharmthera.2009.10.005.
Musumeci, G., et al., Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF-alpha and of IL-1beta in experimental autoimmune encephalomyelitis. Neurobiol Dis, 2011. 43(3): p. 669–77 DOI: 10.1016/j.nbd.2011.05.018.
Nguyen, T.L., et al., Transient receptor potential vanilloid type 1 channel may modulate opioid reward. Neuropsychopharmacology, 2014. 39(10): p. 2414–22 DOI: 10.1038/npp.2014.90.
Miyanohara, J., et al., A pathophysiological role of TRPV1 in ischemic injury after transient focal cerebral ischemia in mice. Biochem Biophys Res Commun, 2015. 467(3): p. 478–83 DOI: 10.1016/j.bbrc.2015.10.027.
Nam, J.H., et al., TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. Brain, 2015. 138(Pt 12): p. 3610-22 DOI: 10.1093/brain/awv297.
Gupta, S. and B. Sharma, Pharmacological modulation of I(1)-imidazoline and alpha2-adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur J Pharmacol, 2014. 723: p. 80–90 DOI: 10.1016/j.ejphar.2013.12.003.
Gupta, S. and B. Sharma, Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease. Pharmacol Biochem Behav, 2014. 122: p. 122–35 DOI: 10.1016/j.pbb.2014.03.022.
Chang, Y.H., S.T. Lee, and W.W. Lin, Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem, 2001. 81(4): p. 715–23 DOI: 10.1002/jcb.1103.
Chen, C.W., et al., Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogs in macrophages. Br J Pharmacol, 2003. 140(6): p. 1077–87 DOI: 10.1038/sj.bjp.0705533.
Kim, C.S., et al., Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell Signal, 2003. 15(3): p. 299–306 DOI: 10.1016/s0898-6568(02)00086-4.
Yin, N., et al., Paeoniflorin relieves LPS-induced inflammatory pain in mice by inhibiting NLRP3 inflammasome activation via transient receptor potential vanilloid 1. J Leukoc Biol, 2020. 108(1): p. 229–241 DOI: 10.1002/JLB.3MA0220-355R.
Jin, L., et al., Metformin Inhibits NLR Family Pyrin Domain Containing 3 (NLRP)-Relevant Neuroinflammation via an Adenosine-5'-Monophosphate-Activated Protein Kinase (AMPK)-Dependent Pathway to Alleviate Early Brain Injury After Subarachnoid Hemorrhage in Mice. Front Pharmacol, 2022. 13: p. 796616 DOI: 10.3389/fphar.2022.796616.
Xia, D.Y., et al., SIRT1 Promotes M2 Microglia Polarization via Reducing ROS-Mediated NLRP3 Inflammasome Signaling After Subarachnoid Hemorrhage. Front Immunol, 2021. 12: p. 770744 DOI: 10.3389/fimmu.2021.770744.
Zhang, Z.H., et al., Luteolin Confers Cerebroprotection after Subarachnoid Hemorrhage by Suppression of NLPR3 Inflammasome Activation through Nrf2-Dependent Pathway. Oxid Med Cell Longev, 2021. 2021: p. 5838101 DOI: 10.1155/2021/5838101.
Li, C., et al., A mini-review on ion fluxes that regulate NLRP3 inflammasome activation. Acta Biochim Biophys Sin (Shanghai), 2021. 53(2): p. 131–139 DOI: 10.1093/abbs/gmaa155.

Supplementary Table 1 is not available with this version.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

TRPV1 modulated NLRP3 inflammasome activation via calcium in experimental subarachnoid hemorrhage

Status:

Version 1

Abstract

Figures

Introduction

Methods And Materials

Mouse models of SAH and drugs administration

Results

TRPV1 upregulated post-SAH

Discussion

Declarations

References

Supplementary Table 1

Additional Declarations

Status:

Version 1